Select a medication above to begin.
Blenrep (belantamab mafodotin-blmf)
belantamab mafodotin
Black Box Warnings .
Appropriate Use
restricted distribution program (BLENREP REMS) due to ocular toxicity risk; prescribers, healthcare facility must be certified, and patients must be enrolled in the program; 1-855-690-9572 or www.BLENREPREMS.com for more information
Ocular Toxicity
caused by changes in corneal epithelium resulting in vision changes, including severe visual impairment, blurred vision, dry eyes; corneal ulcers, including cases with infection, also occurred; ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated; 83% of patients required dose modification; withhold or permanently D/C tx based on severity
Adult Dosing .
Dosage forms: INJ
Restricted Distribution in US
- [1-855-690-9572 or www.BLENREPREMS.com for more information]
Special Note
- [drug name clarification]
- Info: nonproprietary name = belantamab mafodotin-blmf
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, concomitant meds, and dosing including toxicity-related dose adjustments
multiple myeloma, relapsed or refractory
- [2.5 mg/kg/dose IV q3wk]
- Info: for pts who have received at least 2 prior tx, including a proteasome inhibitor and an immunomodulatory agent; part of multi-drug chemo regimen for 1st 8 cycles
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.